A chat about the Ravu-Pregnancy Registry
Recently I wrote an article about a clinical study which is an Ravulizumab pregnancy registry in the USA. Then tried to…
Recently I wrote an article about a clinical study which is an Ravulizumab pregnancy registry in the USA. Then tried to…
After years of waiting, eculizumab Soliris(R) has been approved by India’s Central Drugs Standard Control Organisation (CDSCO) as an approved drug…
In 2023 a group from the aHUS community met with the FDA to talk to them about living with aHUS and…
Complement inhibition treatment discontinuation is a topic that Global Action has led on in the aHUS patient advocacy world for several…
Recently a novel article about complement inhibitor treatment discontinuation was published. Novel because of the research method used to produce its…
There are now licensed biosimilars to eculizumab available in Europe and also in the USA ( see previous article and further…
In making a choice aHUS patients’ preferences among treatments like eculizumab (and its biosimulars) , ravulizumab, crovalimab, and iptacopan it largely…
It is now just over 3 months since a discontinuing treatment decision making model was proposed to help aHUS patients make…
Introduction Atypical Hemolytic Uremic Syndrome (aHUS) is a rare, life-threatening disease that remains largely unfamiliar to the general public and even…